Note 9 - Warrants

As of December 31, 2025 and 2024, the Company had outstanding warrants with no changes in the number of warrants issued or outstanding during the periods presented. Accordingly, there were no warrant issuances, exercises, or expirations during the years presented.

On August 31, 2022, the Company issued an aggregate of 150,000 warrants to purchase shares of its common stock to John P. O’Shea (37,129 warrants), Marika Tonay (734 warrants), and Jonathan Braun (112,137 warrants) in consideration for services rendered. On August 31, 2022, John P. O’Shea transferred 18,564 of his warrants to Jennifer L. O’Shea and retained the remaining 18,565 warrants. The warrants vested immediately upon issuance, are exercisable at a price of $1.20 per share, and expire on August 31, 2027.

As of December 31, 2025, and 2024, an aggregate of 150,000 warrants to purchase shares of the Company’s common stock remained outstanding.

No warrants were exercised, modified, or cancelled during the years ended December 31, 2025, and 2024. Accordingly, the Company did not recognize any stock-based compensation expense related to these warrants during the years presented.

The following are changes and balances for common share equivalent due to outstanding warrants:

 Schedule of Changes and Balances for Common Share Equivalent Due to Outstanding Warrants

As of December 31, 2025, the weighted average remaining contractual life of the warrants was approximately 1.7 years.